These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 38607318)

  • 21. EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex.
    Hsu JH; Rasmusson T; Robinson J; Pachl F; Read J; Kawatkar S; O' Donovan DH; Bagal S; Code E; Rawlins P; Argyrou A; Tomlinson R; Gao N; Zhu X; Chiarparin E; Jacques K; Shen M; Woods H; Bednarski E; Wilson DM; Drew L; Castaldi MP; Fawell S; Bloecher A
    Cell Chem Biol; 2020 Jan; 27(1):41-46.e17. PubMed ID: 31786184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity.
    Sinatra L; Yang J; Schliehe-Diecks J; Dienstbier N; Vogt M; Gebing P; Bachmann LM; Sönnichsen M; Lenz T; Stühler K; Schöler A; Borkhardt A; Bhatia S; Hansen FK
    J Med Chem; 2022 Dec; 65(24):16860-16878. PubMed ID: 36473103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IKZF2 Degradation: It's Time to Take into Account it When Designing Cereblon-Based PROTACs.
    Li M
    Chembiochem; 2024 Aug; 25(16):e202400365. PubMed ID: 38802326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Target protein localization and its impact on PROTAC-mediated degradation.
    Simpson LM; Glennie L; Brewer A; Zhao JF; Crooks J; Shpiro N; Sapkota GP
    Cell Chem Biol; 2022 Oct; 29(10):1482-1504.e7. PubMed ID: 36075213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of a Highly Potent and Selective BRD9 PROTAC Degrader Based on E3 Binder Investigation for the Treatment of Hematological Tumors.
    Duan H; Zhang J; Gui R; Lu Y; Pang A; Chen B; Shen L; Yu H; Li J; Xu T; Wang Y; Yao X; Zhang B; Lin N; Dong X; Zhou Y; Che J
    J Med Chem; 2024 Jul; 67(13):11326-11353. PubMed ID: 38913763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/Aiolos.
    Meng F; Xu C; Park KS; Kaniskan HÜ; Wang GG; Jin J
    J Med Chem; 2022 Aug; 65(15):10611-10625. PubMed ID: 35895319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders.
    Hu J; Wei J; Yim H; Wang L; Xie L; Jin MS; Kabir M; Qin L; Chen X; Liu J; Jin J
    J Med Chem; 2020 Dec; 63(24):15883-15905. PubMed ID: 33284613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins.
    Shirasaki R; Matthews GM; Gandolfi S; de Matos Simoes R; Buckley DL; Raja Vora J; Sievers QL; Brüggenthies JB; Dashevsky O; Poarch H; Tang H; Bariteau MA; Sheffer M; Hu Y; Downey-Kopyscinski SL; Hengeveld PJ; Glassner BJ; Dhimolea E; Ott CJ; Zhang T; Kwiatkowski NP; Laubach JP; Schlossman RL; Richardson PG; Culhane AC; Groen RWJ; Fischer ES; Vazquez F; Tsherniak A; Hahn WC; Levy J; Auclair D; Licht JD; Keats JJ; Boise LH; Ebert BL; Bradner JE; Gray NS; Mitsiades CS
    Cell Rep; 2021 Jan; 34(1):108532. PubMed ID: 33406420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of E3 Ligase Ligands for Target Protein Degradation.
    Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic.
    Li D; Yu X; Kottur J; Gong W; Zhang Z; Storey AJ; Tsai YH; Uryu H; Shen Y; Byrum SD; Edmondson RD; Mackintosh SG; Cai L; Liu Z; Aggarwal AK; Tackett AJ; Liu J; Jin J; Wang GG
    Oncogene; 2022 Jun; 41(24):3328-3340. PubMed ID: 35525905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective Wee1 degradation by PROTAC degraders recruiting VHL and CRBN E3 ubiquitin ligases.
    Aublette MC; Harrison TA; Thorpe EJ; Gadd MS
    Bioorg Med Chem Lett; 2022 May; 64():128636. PubMed ID: 35231578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras.
    Takwale AD; Jo SH; Jeon YU; Kim HS; Shin CH; Lee HK; Ahn S; Lee CO; Du Ha J; Kim JH; Hwang JY
    Eur J Med Chem; 2020 Dec; 208():112769. PubMed ID: 32961381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies.
    Yu X; Xu J; Shen Y; Cahuzac KM; Park KS; Dale B; Liu J; Parsons RE; Jin J
    J Med Chem; 2022 Feb; 65(4):3644-3666. PubMed ID: 35119851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2.
    Liu Z; Hu X; Wang Q; Wu X; Zhang Q; Wei W; Su X; He H; Zhou S; Hu R; Ye T; Zhu Y; Wang N; Yu L
    J Med Chem; 2021 Mar; 64(5):2829-2848. PubMed ID: 33606537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
    Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cereblon target validation using a covalent inhibitor of neosubstrate recruitment.
    Dann GP; Liu H; Nowak RP; Jones LH
    Methods Enzymol; 2023; 681():155-167. PubMed ID: 36764755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of Substituted Phenyl Dihydrouracil as the Novel Achiral Cereblon Ligands for Targeted Protein Degradation.
    Xie H; Li C; Tang H; Tandon I; Liao J; Roberts BL; Zhao Y; Tang W
    J Med Chem; 2023 Feb; 66(4):2904-2917. PubMed ID: 36749666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein degraders - from thalidomide to new PROTACs.
    Ito T
    J Biochem; 2024 Apr; 175(5):507-519. PubMed ID: 38140952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type Cereblon Binders for the Design of PROTACs.
    Steinebach C; Bricelj A; Murgai A; Sosič I; Bischof L; Ng YLD; Heim C; Maiwald S; Proj M; Voget R; Feller F; Košmrlj J; Sapozhnikova V; Schmidt A; Zuleeg MR; Lemnitzer P; Mertins P; Hansen FK; Gütschow M; Krönke J; Hartmann MD
    J Med Chem; 2023 Nov; 66(21):14513-14543. PubMed ID: 37902300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis of novel glutarimide ligands for the E3 ligase substrate receptor Cereblon (CRBN): Investigation of their binding mode and antiproliferative effects against myeloma cell lines.
    Krasavin M; Adamchik M; Bubyrev A; Heim C; Maiwald S; Zhukovsky D; Zhmurov P; Bunev A; Hartmann MD
    Eur J Med Chem; 2023 Jan; 246():114990. PubMed ID: 36476642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.